Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) EBITDA Margin (2021 - 2025)

Mirum Pharmaceuticals (MIRM) has 5 years of EBITDA Margin data on record, last reported at 3.07% in Q4 2025.

  • For Q4 2025, EBITDA Margin rose 2130.0% year-over-year to 3.07%; the TTM value through Dec 2025 reached 4.25%, up 2176.0%, while the annual FY2025 figure was 4.25%, 2176.0% up from the prior year.
  • EBITDA Margin reached 3.07% in Q4 2025 per MIRM's latest filing, down from 1.96% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 1.96% in Q3 2025 and bottomed at 1452.36% in Q4 2021.
  • Average EBITDA Margin over 5 years is 197.72%, with a median of 52.69% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: soared 132994bps in 2022, then skyrocketed 1599bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 1452.36% in 2021, then surged by 92bps to 122.41% in 2022, then skyrocketed by 62bps to 46.85% in 2023, then soared by 48bps to 24.36% in 2024, then soared by 87bps to 3.07% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 3.07% in Q4 2025, 1.96% in Q3 2025, and 3.9% in Q2 2025.